Positioning for Success
As we strategically refine our portfolio and position for success, we are actively out-licensing our historical sGC stimulators, with an aim for those assets to find the ideal pathways for continued development. In addition to our pipeline evolution, we hold a 10% equity stake in Tisento Therapeutics – which could be a potential avenue for long-term value.
This transition reflects our dedication to both legacy investors and new stakeholders as we advance the future of neuropsychiatric care, starting with TRD.
Evolving Our Pipeline
Advancing Innovation
Rather than starting from scratch, our approach leverages:
- Well-established medicines with extensive safety data
- Cutting-edge technologies to enhance treatment precision and effectiveness
- A focus on neuropsychiatric disorders, starting with treatment-resistant depression
To bring safe, effective, and accessible solutions to patients faster at a fraction of traditional development costs.
Olinciguat: Cyclerion has entered into an exclusive license option agreement for its vascular sGC stimulator, olinciguat, with a separate entity, wholly controlled by CVCO Therapeutics, Inc., a clinical stage company focused on microvascular dysfunction in cardiovascular, inflammatory and metabolic disease states.
Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease. In preclinical studies, praliciguat demonstrated extensive distribution to key target tissues including adipose tissue, kidney, heart, and liver; the extensive, extra-vascular distribution of praliciguat has been confirmed in clinical studies.
Zagociguat and CY3018 are CNS-penetrant sGC stimulators that were developed at Cyclerion and were sold to Tisento Therapeutics, Inc., a company in which Cyclerion holds a 10% equity stake. Zagociguat is a clinical-stage CNS-penetrant sGC stimulator that has shown rapid improvement in cerebral blood flow, functional brain connectivity, brain response to visual stimulus, cognitive performance, and biomarkers associated mitochondrial function and inflammation in clinical studies. CY3018 is a CNS-targeted sGC stimulator that preferentially localizes to the brain and has a pharmacology profile that suggests its potential for the treatment of neuropsychiatric diseases and disorders.